Trial Profile
A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs CRS 207 (Primary) ; Tumour cell vaccine-GVAX (Primary) ; Cyclophosphamide
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Aduro BioTech
- 27 Apr 2017 Status changed from discontinued to completed.
- 28 Dec 2015 Planned End Date changed from 1 Nov 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.
- 09 Nov 2015 Updated safety and efficacy data were presented at the 2015 Society for Immunotherapy of Cancer Annual Meeting, according to an Aduro BioTech media release.